1
|
Hojo T, Masuda N, Shibata T, Mizutani T, Shien T, Kinoshita T, Iwatani T, Kanbayashi C, Kitagawa D, Tsuneizumi M, Iwata H. Abstract OT2-01-05: A randomized controlled trial comparing post-operative intensive follow-up with standard follow-up in high-risk breast cancer patients (JCOG1204: INSPIRE). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The standard follow-up after surgery for breast cancer includes periodic interviews, clinical examinations, and mammography, but many institutions are conducting intensive follow-up including periodic computed tomography(CT), magnetic resonance imaging(MRI), and bone scintigraphy in the world, despite the lack of evidence to support this approach. While intensive follow-up may contribute to prolonged survival through earlier diagnosis and treatment of relapse, it has the disadvantages of high effort and costs placed on patients(pts) and healthcare workers, radiation exposure for imaging examinations, and overtreatment owing to false-positive results. Although past two randomized trials could not show significant difference in overall survival (OS), as imaging methods have remarkably improved, leading to the earlier detection of relapse, and medical therapies have remarkably improved in recent years, randomized controlled trials are needed to confirm whether intensive follow-up can really prolong survival sufficiently to offset these disadvantages in high-risk breast cancer pts.
Trial design: This study is a multi-institutional two-arm open label randomized controlled phase III trial being conducted with the participation of 42 hospitals belonging to the Breast Cancer Study Group of Japan Clinical Oncology Group. Eligible pts are randomized either to the intensive follow-up group or to the standard follow-up group; the former will undergo physical examination, bone scintigraphy, chest and abdominal CT, brain MRI/CT and frequent tumor markers, whereas the latter will undergo physical examination at the same frequency and tumor markers will be evaluated once a year. Mammography once a year is planned for both groups. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000012429.
Eligibility criteria: High-risk breast cancer pts, who are expected to have recurrence rates of over 30% within 5 years after surgery. The main inclusion criteria are as follows: four or more axillary nodal metastases in the estrogen receptor (ER) positive pts without neoadjuvant chemotherapy(NC)., axillary node metastases in ER-negative pts without NC, axillary nodal metastases in ER-positive pts with NC, histologically proven residual invasive cancer in the breast or axilla in ER-negative with NC.
Specific Aims: The primary endpoint is OS, and secondary endpoints are disease-free survival, relapse-free survival, distant metastasis–free survival, OS in intrinsic subtypes, actual number of implemented examinations, compliance with pre-specified examinations, and adverse events.
Statistical methods: The primary endpoint will require a total of 538 events to be assessed in order to obtain a statistical power of 80% with a one-sided significance level of 0.05. Thus, the planned sample size to compare the two survival curves is set at 1500 pts, assuming an accrual time of 6 years and a follow-up time of 7 years according to the Schoenfeld and Richter's method.
Present accrual and target accrual: The trial was activated in November 2013. 773 pts have been enrolled by the end of June 2018.
Contact: Principal investigator Takashi Hojo MD tahojo@east.ncc.go.jp
Citation Format: Hojo T, Masuda N, Shibata T, Mizutani T, Shien T, Kinoshita T, Iwatani T, Kanbayashi C, Kitagawa D, Tsuneizumi M, Iwata H. A randomized controlled trial comparing post-operative intensive follow-up with standard follow-up in high-risk breast cancer patients (JCOG1204: INSPIRE) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-01-05.
Collapse
Affiliation(s)
- T Hojo
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - N Masuda
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Shibata
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Mizutani
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Shien
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Kinoshita
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Iwatani
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - C Kanbayashi
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - D Kitagawa
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Tsuneizumi
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| | - H Iwata
- National Cancer Center Hospital East, Chiba, Japan; NHO Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Niigata Cancer Center, Niigata, Japan; Cancer Institute Hospital, Tokyo, Japan; Shizuoka General Hospital, Shizuoka, Japan; Aichi Cancer Center Hospital, Nagoya, Japan
| |
Collapse
|
2
|
Kinoshita T, Ohtani S, Doihara H, Takahashi M, Fujisawa T, Yamamoto N, Aogi K, Hojo T. Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer (RAFAELO study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy270.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Shimomura A, Tamura K, Mizutani T, Shibata T, Hara F, Fujisawa T, Niikura N, Hojo T, Kambayashi C, Saji S, Masuda N, Sawaki M, Yamamoto N, Nagashima F, Shien T, Iwata H. A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Piotrowska-Tomala K, Hojo T, Jonczyk A, Wrobel M, Jankowska K, Skarzynskia D. The Effect of Lysophosphatidic Acid (LPA) on Contractions in Equine Myometrium During the Stages of Fibrosis at the Early and Mid-luteal Phase of the Estrous Cycle. J Equine Vet Sci 2018. [DOI: 10.1016/j.jevs.2018.05.184] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
5
|
Shibuya M, Hojo T, Hase Y, Fujisawa T. Conscious sedation with midazolam intravenously for a patient with Parkinson's disease and unpredictable chorea-like dyskinesia. Br J Oral Maxillofac Surg 2018; 56:546-548. [PMID: 29908706 DOI: 10.1016/j.bjoms.2018.05.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2018] [Accepted: 05/25/2018] [Indexed: 11/17/2022]
Abstract
Oral surgery can be difficult in patients with chorea-like dyskinesia, which is common in those on long-term levodopa medication for Parkinson's disease, and we know of no conclusive evidence to indicate whether conscious sedation with midazolam is effective in such cases. We report a patient in whom levodopa-induced chorea-like dyskinesia disappeared when midazolam was given intravenously for conscious sedation.
Collapse
Affiliation(s)
- M Shibuya
- Department of Dental Anesthesiology, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University.
| | - T Hojo
- Department of Dental Anesthesiology, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University.
| | - Y Hase
- Department of Dental Anesthesiology, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University.
| | - T Fujisawa
- Department of Dental Anesthesiology, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University.
| |
Collapse
|
6
|
Kinoshita T, Takahashi M, Fujisawa T, Yamamoto N, Takanashi M, Aogi K, Hojo T, Yoshida M, Tsuda H. Radiofrequency ablation therapy for early-stage breast cancer: Results from 5 years of follow-up in a prospective multicenter study. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30413-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
7
|
Kinoshita T, Ohtani S, Doihara H, Yamamoto N, Takahashi M, Fujisawa T, Aogi K, Hojo T, Asaga S, Yoshida M, Tsuda H. Abstract P3-13-17: A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-13-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: As the management of breast carcinoma evolves toward less invasive treatments, the next step is the possibility of removing the primary tumor without surgery. The most promising noninvasive ablation technique is radiofrequency ablation (RFA), which can effectively kill tumor cells with a low complication rate. Our preliminary studies of RFA followed by standard surgical resection have indicated that this technique is effective for surgical ablation of small (≤ 2cm) breast tumors without extensive intraductal components (EIC).
Methods: To determine if RFA is oncologically and cosmetically appropriate for the local treatment of primary breast carcinoma, this multi-center prospective study used RFA as the sole local treatment of breast tumors ≤ 1.5cm in size on ultrasound and MRI. Exclusion criteria include receiving of preoperative chemotherapy, or the presence of invasive lobular carcinoma or invasive ductal carcinoma with suspicious EIC. After confirmation that the standard baseline core biopsy for diagnosis and measurement of tumors markers (ER, PgR, HER-2/neu expression and the presence of the Ki-67 proliferative marker) have been obtained, consent will be obtained and the patient scheduled RFA. All patients received adjuvant radiation therapy. The use and choice of systemic therapy will be based on the information from the baseline core biopsy. The first primary endpoints of this study is successful tumor ablation, as evidenced by negative findings on vacuum-assisted or core biopsies and imaging studies after RFA. The second primary endpoints is the incidence of procedure related adverse events. Forty patients with small tumors that are clearly identifiable and measurable by ultrasound and MRI were enrolled. The response to ablation was evaluated with both vacuum-assisted or core biopsies and imaging studies every 3 months during the first year. The long-term outcomes were assessed using quality of life measurement scales and imaging studies every 6 months thereafter through year 5.
Results: Of the 58 patients who participated in this study, 55 completed the protocol. In 48 of the 55 (87%) treated patients, successful tumor ablation, as determined by negative findings on vacuum-assisted or core biopsies and imaging studies, was confirmed. The remaining 7 patients with biopsies positive for residual tumor underwent surgical resection. There were no local or distant recurrences in treated 55 patients with a median follow up of 47 (range 36-73) months.
Conclusions: RFA can be safely used alone in patients with small breast tumors, provided that local tumor control must be regularly assessed by image-guided vacuum-assisted or core biopsies after ablation. RFA has several potential advantages over lumpectomy for the treatment of early stage breast cancer.
Citation Format: Kinoshita T, Ohtani S, Doihara H, Yamamoto N, Takahashi M, Fujisawa T, Aogi K, Hojo T, Asaga S, Yoshida M, Tsuda H. A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-17.
Collapse
Affiliation(s)
- T Kinoshita
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - S Ohtani
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - H Doihara
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - N Yamamoto
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - M Takahashi
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - T Fujisawa
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - K Aogi
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - T Hojo
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - S Asaga
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - M Yoshida
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - H Tsuda
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| |
Collapse
|
8
|
Hironaka A, Tsuda H, Yoshida M, Shimizu C, Tamura K, Fujiwara Y, Hojo T, Kinoshita T, Maeshima A, Hiraoka N. P019 Histopathological features of operable breast cancer detected in women younger than 35 years. Breast 2015. [DOI: 10.1016/s0960-9776(15)70069-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Ogura T, Kinoshita T, Jimbo K, Asaga S, Hojo T. P313 A new predictive score for axillary lymph node metastases in breast cancer patients. Breast 2015. [DOI: 10.1016/s0960-9776(15)70343-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Wu LJ, Qin Y, Hojo T, Li YY. Upgrading of anaerobic digestion of waste activated sludge by a hyper-thermophilic–mesophilic temperature-phased process with a recycle system. RSC Adv 2015. [DOI: 10.1039/c5ra08811a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A hyper-thermophilic–mesophilic temperature-phased anaerobic digestion with a recycle system effectively upgraded the mesophilic digestion of waste activated sludge.
Collapse
Affiliation(s)
- L. J. Wu
- Department of Civil and Environmental Engineering
- Graduate School of Engineering
- Tohoku University
- Sendai
- Japan
| | - Y. Qin
- Department of Frontier Science for Advanced Environment
- Graduate School of Environmental Studies
- Tohoku University
- Sendai
- Japan
| | - T. Hojo
- Department of Civil and Environmental Engineering
- Graduate School of Engineering
- Tohoku University
- Sendai
- Japan
| | - Y. Y. Li
- Department of Civil and Environmental Engineering
- Graduate School of Engineering
- Tohoku University
- Sendai
- Japan
| |
Collapse
|
11
|
Kikuyama M, Akashi-Tanaka S, Hojo T, Kinoshita T, Ogawa T, Seto Y, Tsuda H. Utility of intraoperative frozen section examinations of surgical margins: implication of margin-exposed tumor component features on further surgical treatment. Jpn J Clin Oncol 2014; 45:19-25. [DOI: 10.1093/jjco/hyu158] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Ogura T, Kinoshita T, Jimbo K, Asaga S, Hojo T. The New Intraoperative Diagnostic Method to Predict Non-Slns Status in Breast Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.59] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Hojo T, Tamura K, Masuda N, Inoue K, Kinoshita T, Fujisawa T, Hara F, Saji S, Asaga S, Anan K, Yamamoto N, Wada N, Takahashi M, Nakagami K, Kuroi K, Iwata H. Abstract P3-02-06: Survival impact of early detection of recurrence after surgery in early breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-02-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Object: Annual mammography and physical examination as the follow-up tests after surgery were recommended to early breast cancer patients based on the two randomized clinical trials (GIVIO and Rosselli Del Turco) which were reported in 1990s. Whereas, radiological imaging and blood test (serum tumor marker) for early detection of recurrence are not recommended due to the lack of evidence from clinical trial. However, the imaging techniques (helical CT, bone scan, PET/CT. MRI et al) to detect minute lesions and therapeutic options for metastatic breast cancer have been remarkably advanced since then. In fact, routine radiological examinations after surgery were performed in several Japanese hospitals for aiming early detection of recurrence as the clinical practice.
We here evaluate the possible benefit of early detection of recurrence by radiological and laboratory examinations during post-operative follow-up period.
Methods: Clinical information of breast cancer patients who were diagnosed as recurrence after surgery during 2005–2006 was collected from 30 hospitals in Japan. Clinical and pathological characteristics such as molecular subtype of breast cancer, survival time from initial therapy or 1st recurrence, detection methods and symptomatic information when they diagnosed as metastasis were analyzed retrospectively.
Results: As the routine examination of post-operative follow-up, serum tumor maker, chest x-ray/CT, abdominal US/CT and bone scan were done in 95%, 57%, 38%, 24% of 30 hospitals, respectively. Of the 698 patients individually evaluated in this analysis, 248 had loco-regional recurrences and 450 had distant metastases. The first distant metastatic site were 35% in bone, 30% in lung, 17% in liver and 11% in lymph node, respectively. All individual patients are divided into symptomatic (45.7%) or asymptomatic groups (54.3%) at the detection of metastases. Asymptomatic metastases were detected by serum tumor marker (26%), bone scan (18%), chest x-ray (17%), chest CT (17%), abdominal US (11%) and abdominal CT (5%), respectively. The median disease-free interval (DFI) was 3.0 years in both groups, but the median survival time after the diagnosis of recurrence to death were 3.7 years in asymptomatic patients and 3.0 years in symptomatic patients, respectively. In addition, asymptomatic group had significantly superior overall survival (from primary surgery to death) than symptomatic group with oligo-metastases such as limited organ disease (P < 0.001).
Conclusions: Our data may support the hypothesis that early detection of breast cancer recurrences has beneficial impact on survival. Randomized clinical trial would be warranted to prove this hypothesis, and we are currently planning this.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-02-06.
Collapse
Affiliation(s)
- T Hojo
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - K Tamura
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - N Masuda
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - K Inoue
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - T Kinoshita
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - T Fujisawa
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - F Hara
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - S Saji
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - S Asaga
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - K Anan
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - N Yamamoto
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - N Wada
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - M Takahashi
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - K Nakagami
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - K Kuroi
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - H Iwata
- National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Cente, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| |
Collapse
|
14
|
Jimbo K, Kinoshita T, Suzuki J, Asaga S, Hojo T, Yoshida M, Tsuda H. 163. A new development in sentinel lymph node biopsy in breast cancer using a combination of molecular and histological methods. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
15
|
Jimbo K, Kinoshita T, Hojo T, Asaga S, Suzuki J. 539 A New Development in Sentinel Lymph Node Biopsy in Breast Cancer Using a Combination of Molecular and Histological Methods. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70604-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Asaga S, Kinoshita T, Hojo T, Suzuki J, Jimbo K, Tsuda H. 425 Prognostic Factors for Triple Negative Breast Cancer Patients with Preoperative Systemic Chemotherapy. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70491-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Kinoshita T, Tsuda H, Hojo T, Asaga S, Suzuki J, Jimbo K, Yamamoto N, Fujisawa T, Takabatake D, Wada N. 531 Image-guided Radiofrequency Ablation in Patients with Primary Breast Carcinoma-a Multicenter Study of 40 Patients-. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70596-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Nagatsuma AK, Shimizu C, Tsuda H, Saji S, Hojo T, Sugano K, Fujiwara Y. P2-12-21: Impact of Recent Parity on Histopathological Tumor Features and Outcome of Young Women with Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Younger age has been associated with worse outcome in breast cancer patients (pts) and recent parity has been epidemiologically identified as worse prognostic factor among women with breast cancer. The objective of this study was to explore potential factors associated with worse prognosis in young breast cancer pts, and to demonstrate the impact of parity on the histopathological tumor feature and patient outcome.
Materials and Methods: We retrospectively analyzed 634 early breast cancer pts younger than 45 years old who underwent surgery between 2000 and 2009. For statistical analysis, Pearson's and Fisher's exact test were used. Survival analysis was performed only for pts diagnosed before 2006 in order to obtain a minimum follow up 5 years.
Results: 108 women were diagnosed within 5 years since last parity (Group A), 216 were diagnosed > 5 years since last parity (Group B) and 310 were nulliparous (Group C). Median age at diagnosis was 37 (range 26–44), 41 (range 32–44), and 38.5 (range 22–44) and family history (FH) of breast and/or ***ovarian cancer within second degree was found in 23, 22, and 23% of the pts in Groups A, B, and C, respectively. In Groups A, B and C, clinical stage was III in 22, 10 and 12% (p= .025), ER was positive in 65, 69 and 70% (p= .650), PgR was positive in 64, 75 and 74% (p= .057), and HER2 was positive in 25, 14 and 14% (p=.017), respectively. Tumors in Group A had higher histological grade (grade 3: 60/44/47%, p=.019), higher nuclear grade (grade 3: 61/47/48%, p=.036) and more lymph vessel invasion (61/52/45%, p=.015) compared to those in Groups B and C, respectively. Median follow up time was 85.1 months (range 1.8−137.1 months) during which there were 61 deaths. In univariate analysis, age and FH were not correlated with overall survival (OS). OS in Group A was significantly lower than in Group B (hazard ratio (HR) 3.51, 95% confidential interval (CI) 1.80−6.84, p<.001) and in Group C (HR 2.42, 95%CI 1.36−4.29, p=.002), while OS did not differ significantly between Groups B and C. In the pts without FH, the HR of cancer death was more pronounced in Group A than in Group B (HR 4.25, 95%CI 1.97−9.14, p<.001) or Group C (HR 2.67, 95%CI 1.43−5.01, p=.002), while there was no significant difference among the groups in pts with FH. In multivariate analysis among the pts without FH, lymph vessel invasion (HR 4.51, 95%CI 1.89−10.76, p=.001), Group A women (HR 2.28, 95%CI 1.25−4.17, p=.007), histological grade 3 (HR 2.72, 95%CI 1.28−5.77, p=.009), PgR negativity (HR 2.23, 95%CI 1.19−4.18, p=.013) and clinical stage II and III (HR 2.92, 95%CI 1.04−8.21, p=.04) were significantly associated with poor prognosis, adjusting for age.
Conclusion: Recent parity was associated with worse histopathological features in breast cancer of women younger than 45. It was also associated with worse outcome, especially among pts without FH. Recent parity seems to be a confounding factor for the worse outcome in young breast cancer patients, which justifies further studies to elucidate underlying biology.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-21.
Collapse
Affiliation(s)
- AK Nagatsuma
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| | - C Shimizu
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| | - H Tsuda
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| | - S Saji
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| | - T Hojo
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| | - K Sugano
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| | - Y Fujiwara
- 1National Cancer Center Hospital; Saitama Medical University International Medical Center; Tochigi Cancer Center Research Institute
| |
Collapse
|
19
|
Kagami Y, Morota M, Okamoto H, Mayahara H, Ito Y, Sumi M, Itami J, Akashi S, Hojo T, Kinoshita T. Prospective Trial of Accelerated Partial Breast Irradiation with Once-a-day Treatment in Early Stage Breast Cancer: Report of Short-term Outcome. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Suzuki J, Hojo T, Jimbo K, Asaga S, Kinoshita T. Risk of breast cancer among Japanese women with a positive family history. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
191 Background: Most breast cancer cases are sporadic, rather than associated with inherited gene mutations, such as BRCA1 and BRCA2. However, women with a family history of breast cancer are at increased risk of developing breast cancer compared to those women without any family history, even if they lack these gene mutations. Methods: We analyzed 10892 patients including bilateral breast cancer cases (total of 11398 breast cancers) who underwent surgery at our hospital between 1962 and 2009. We excluded 295 cases whose family history data were not available. Clinical and pathological differences between following patient groups were tested; 9528 patients or 9955 cancers (88%) with negative family history (FH-), 896 patients or 951 cancers (8%) who had at least one first-degree relative with breast cancer (1FH+), 468 patients or 492 cancers (4%) who had second-degree relative with breast cancer (2FH+), and 1364 patients or 1443 cancers (12%) with family history regardless of first- or second-degree relative (FH+). Significance was established at a p-value of < 0.05. Results: Among the family members, sisters were more likely to have treated for breast cancer (38% in FH+ group), followed by mothers (27%), aunts (26%), grandmothers (7%), and daughters (2%). The incidence of developing contralateral breast cancer was significantly higher in 1FH+ group, compared to patients in FH- and 2FH+ groups. No other factors showed any significant difference, including the incidence of cancer in other organs, pathological characteristics, and age of onset, although BRCA1 and BRCA2 mutation may be associated with increased risk of developing breast cancer at younger age. Outcome studies with available data did not show any significant difference in overall survival between FH+ and FH- patients. Conclusions: A Japanese woman with a positive family history has a higher risk of developing breast cancer than women without any close relatives with breast cancer, similar to the results reported in Western countries where prevalence of breast cancer is higher. Regular checkup of contralateral breast is important for those patients whose first-degree relatives have also been diagnosed with breast cancer.
Collapse
Affiliation(s)
- J. Suzuki
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Hojo
- National Cancer Center Hospital, Tokyo, Japan
| | - K. Jimbo
- National Cancer Center Hospital, Tokyo, Japan
| | - S. Asaga
- National Cancer Center Hospital, Tokyo, Japan
| | | |
Collapse
|
21
|
Kinoshita T, Hojo T, Asaga S, Suzuki J, Jimbo K, Tamura N. Study of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
104 Background: Despite the increasing use of both sentinel lymph node biopsy (SLNB) and preoperative chemotherapy (PST) in patients with operable breast cancer, there is still limited information on the feasibility and accuracy of SLNB following PST. In this study, the feasibility and accuracy of SLNB for breast cancer patients with clinically negative lymph nodes after PST were investigated. In addition, conditions that may affect SLN biopsy detection and false-negative rates with respect to clinical tumor response and clinical tumor/nodal status before PST were analyzed. Methods: Between 2003 and 2008, 200 patients with stage II and III breast cancer previously treated with PST were enrolled in this study. The eligible criteria for PST were (a) primary tumor > 3cm or (b) positive axillary lymph node status on initial examination. FNA biopsy was performed for clinically or ultrasonographically suspicious axillary lymph nodes. The patients then underwent SLNB, which involved a combination of intradermal injection over the tumor of radiocolloid and subareolar injection of blue dye. This was followed by Level I/II axillary lymph node dissection (ALND). Results: The median patient age was 49 years, and the median primary tumor size was 4.9 cm. The overall SLN identification rate was 94.5% (189 of 200). In 178/189 patients (94%) the SLN accurately predicted the axillary status. Eleven patients had a false-negative SLN biopsies, yielding a false-negative rate of 12.9%. There were no significant differences in the SLN identification rate according to tumor classifications before PST, the clinical nodal status before PST, the clinical tumor response after PST, or pathological response of the tumor after PST, although the SLN identification rate tended to be lower in patients with a T4 primary tumor. Conclusions: Our data and some reports suggested that SLNB was feasible method for axillary staging in breast cancer patients who received PST even in patients who initially with lymph node positive disease. However, false-negative rate of SLNB in patients with clinical and pathological complete tumor response tended to be higher than other group.
Collapse
Affiliation(s)
| | - T. Hojo
- National Cancer Center Hospital, Tokyo, Japan
| | - S. Asaga
- National Cancer Center Hospital, Tokyo, Japan
| | - J. Suzuki
- National Cancer Center Hospital, Tokyo, Japan
| | - K. Jimbo
- National Cancer Center Hospital, Tokyo, Japan
| | - N. Tamura
- National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
22
|
Nagao T, Kinoshita T, Tamura N, Hojo T, Morota M, Kagami Y. Locoregional recurrence risk factor and indications for postmastectomy radiotherapy in Japanese patients with tumors 5 cm or larger. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
127 Background: Locoregional recurrence (LRR) after mastectomy reduces the patient’s quality of life and survival. There is a consensus that postmastectomy radiotherapy (PMRT) helps achieve locoregional control and reduces LRR. However, in patients with large tumors, the question of which variables affect the likelihood of LRR and the role of PMRT has been the subject of substantial controversy. This study investigated what are risk factors for LRR and the efficacy of PMRT in this Japanese patient population. Methods: This study examined 589 cases of invasive breast carcinoma with tumors 5 cm or larger from 1998 to 2008. We divided the study population into 3 groups: patients with negative nodes, 1-3 positive nodes, and ≥4 positive nodes. The relationship between various clinicopathological variables and LRR was examined and the relationship between LRR and PMRT was estimated. Results: During the median follow-up was 44.2 months, 38 (6.5%) patients experienced LRR. In the multivariate analysis, independent predictors of LRR include pectoral invasion in patients with 1-3 positive nodes, and severity lymphatic invasion, estrogen receptor-negative status, and nodal ratio of positive/excised nodes ≥ 0.50 in patients with ≥4 positive nodes. In patients without positive nodes, none of the examined variables were significantly associated with LRR. PMRT did not improve the outcome of the patients at highest risk who had these variables. Conclusions: The efficacy of PMRT in patients with large tumors was not shown. In the context of systemic therapy and adequate lymph node dissection, PMRT by itself had a limited role in providing locoregional control. Due to the very low incidence of LRR observed, PMRT was not necessary for patients with large tumors without lymph node metastasis. The indication for PMRT in patients with metastatic nodes remains controversial.
Collapse
Affiliation(s)
- T. Nagao
- National Cancer Center Hospital, Tokyo, Japan
| | | | - N. Tamura
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Hojo
- National Cancer Center Hospital, Tokyo, Japan
| | - M. Morota
- National Cancer Center Hospital, Tokyo, Japan
| | - Y. Kagami
- National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
23
|
Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H. Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast. Br J Cancer 2011; 105:698-708. [PMID: 21811256 PMCID: PMC3188933 DOI: 10.1038/bjc.2011.279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background: We previously reported that the primary tumour/vessel tumour/nodal tumour (PVN) classification is significantly superior to the UICC pTNM classification and the Nottingham Prognostic Index for accurately predicting the outcome of patients with invasive ductal carcinoma of the breast in a manner that is independent of the nodal status and the hormone receptor status. Methods: The purpose of the present study was to compare the outcome predictive power of a modified PVN classification to that of the newly devised pathological UICC pTNM classification and the reclassified Nottingham Prognostic Index in a different group of patients with invasive ductal carcinoma (n=1042) using multivariate analyses by the Cox proportional hazard regression model. Results: The modified PVN classification clearly exhibited a superior significant power, compared with the other classifications, for the accurate prediction of tumour recurrence and tumour-related death among patients with invasive ductal carcinoma in a manner that was independent of the nodal status, the hormone receptor status, and adjuvant therapy status. Conclusion: The modified PVN classification is a useful classification system for predicting the outcome of invasive ductal carcinoma of the breast.
Collapse
Affiliation(s)
- T Hasebe
- Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Kinoshita T, Hojo T, Nagao T, Tamura N, Tanaka S, Fujiwara Y. P241 Sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients. Breast 2011. [DOI: 10.1016/s0960-9776(11)70187-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
25
|
Hojo T, Kinoshita T, Wada N, Imoto S, Tamura N, Nagao T, Ando M, Katsumata N, Fujiwara Y. Abstract P1-12-07: Neo-Adjuvant Exemestane in Post Menopausal Estrogen and/or Progesterone Receptor Positive Breast Cancer: A Randomized Phase II Trial To Investigate Optimal Duration (4 Month Versus 6 Month) of Preoperative Endocrine Therapy (PTEX46 Trial). Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-12-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Since the 1990s, primary endocrine therapy has been considered the gold standard in the adjuvant and metastatic treatment settings for estrogen and/or progesterone receptor (ER and/or PgR) positive breast cancer. This therapy has also been shown to be effective as neo-adjuvant endocrine therapy in these indications. In recent years, the focus of clinical interest has shifted to the third-generation aromatase inhibitors from tamoxifen. The optimal treatment duration time and causal relationship between neo-adjuvant endocrine therapy and survival, however, are not clear. We therefore conducted the present study to investigate the potential benefits of neo-adjuvant exemestane (E) therapy with the goal of identifying the optimal treatment duration (4 months versus 6 months).
Methods: Conducted at three hospitals in Japan, this study was a multicenter, randomized phase II trial of pre-operative E treatment in postmenopausal women with untreated primary breast cancer. Fifty postmenopausal women with ER positive and/or PgR positive invasive breast cancer were randomly assigned to E (25 mg/day) for 4 months (4 mo) or E (25 mg/day) for 6 months (6 mo). All patient data were collected by UMIN and were analyzed by the National Cancer Center in Japan. Tumor regression (by clinical examination, ultrasound, and MRI), pathological response, shift towards breast-conserving surgery, and safety assessments were the main outcome measures.
Results: Of the 50 patients that enrolled, 28 patients had undergone surgery. The mean ages in the 4 mo and 6 mo treatment groups were 66.7 years and 66.8 years, respectively. No significant differences in the patient characteristics were found in the two groups. The response rates (partial or complete responses) by clinical examination in the 4 mo and 6 mo groups were 37.5% and 50%, respectively. Pathological responses (minimal response or better) were found in 13.3% and 41.7% of patients and a partial mastectomy was performed in 50.0% and 58.3% of patients after 4 mo and 6 mo, respectively.
Conclusion: To date, the results of this study demonstrate that treatment with E for 6 mo was more efficacious than treatment with E for 4 mo. Further work is in progress to obtain data from additional patients and to identify the optimal duration of neo-adjuvant E.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-12-07.
Collapse
Affiliation(s)
- T Hojo
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - T Kinoshita
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - N Wada
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - S Imoto
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - N Tamura
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - T Nagao
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - M Ando
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - N Katsumata
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - Y. Fujiwara
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| |
Collapse
|
26
|
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2010; 22:1302-1307. [PMID: 21109570 DOI: 10.1093/annonc/mdq585] [Citation(s) in RCA: 132] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Antibody-dependent-mediated cytotoxicity (ADCC) is one of the modes of action for trastuzumab. Recent data have suggested that fragment C γ receptor (FcγR) polymorphisms have an effect on ADCC. This prospective phase II trial aimed to evaluate whether these polymorphisms are associated with clinical efficacies in patients who received trastuzumab. PATIENTS AND METHODS Patients in a neoadjuvant (N) setting received Adriamycin and cyclophosphamide followed by weekly paclitaxel/trastuzumab. Patients in a metastatic (M) setting received single trastuzumab until progression. In total, 384 distinct single nucleotide polymorphisms of different FcγR, HER2, and fucosyltransferase loci were assessed. RESULTS Fifteen operable and 35 metastatic HER2-positive breast cancer patients were enrolled in each of the N and M settings, respectively. The FcγR2A-131 H/H genotype was significantly correlated with the pathologically documented response (pathological response) (P = 0.015) and the objective response (P = 0.043). The FcγR3A-158 V/V genotype was not correlated with the pathological response, but exhibited a tendency to be correlated with the objective response. Patients with the FcγR2A-131 H/H genotype had significantly longer progression-free survival in the M setting (P = 0.034). CONCLUSION The FcγR2A-131 H/H polymorphism predicted the pathological response to trastuzumab-based neoadjuvant chemotherapy in early-stage breast cancer, and the objective response to trastuzumab in metastatic breast cancer.
Collapse
Affiliation(s)
- K Tamura
- Departments of Breast and Medical Oncology.
| | - C Shimizu
- Departments of Breast and Medical Oncology
| | - T Hojo
- Breast Surgery, National Cancer Center Hospital, Tokyo
| | | | - T Kinoshita
- Breast Surgery, National Cancer Center Hospital, Tokyo
| | - K Yonemori
- Departments of Breast and Medical Oncology
| | - T Kouno
- Departments of Breast and Medical Oncology
| | | | - M Ando
- Departments of Breast and Medical Oncology
| | - K Aogi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Ehime
| | - F Koizumi
- Shien Lab, National Cancer Center Hospital, Tokyo
| | - K Nishio
- Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
| | - Y Fujiwara
- Departments of Breast and Medical Oncology
| |
Collapse
|
27
|
Ishino H, Kawahito Y, Hamaguchi M, Takeuchi N, Tokunaga D, Hojo T, Wada M, Yamamoto A, Kadoya M, Tsubouchi Y, Kohno M, Nakada H. Expression of Tn and sialyl Tn antigens in synovial tissues in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28:246-249. [PMID: 20483047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2009] [Accepted: 11/12/2009] [Indexed: 05/29/2023]
Abstract
OBJECTIVES The carbohydrate chains represented by mucins (MUCs) are expressed by a variety of normal and malignant secretory epithelial cells and induce a variety of immunoreactions. Tn and sialyl Tn antigens are tumour-associated carbohydrate antigens which are borne on the core proteins of mucins. The purpose of this study is to investigate the existence of tumour-associated carbohydrate antigens in rheumatoid arthritis (RA). METHODS . We examined the expression of Tn and sialyl Tn antigens in synovial tissues from RA and osteoarthritis (OA) patients by immunohistochemistry. In addition, mucins from synovial fluid (SF) from RA patients are purified by gel filtration and density gradient ultracentrifugation and the existence of these antigens examined by dot and Western blotting. RESULTS We found that Tn and sialyl Tn antigens were strongly expressed in synovial cells and infiltrating mononuclear cells on the sublining layer and lymphoid follicles in synovial tissues in RA compared with those in osteoarthritis. Tn and sialyl Tn antigens were detected in purified mucins of SF from RA patients. CONCLUSIONS Tumour-like synovial hyperplasia cells expressed Tn and sialyl Tn antigens. This finding suggests that the mucins exhibiting with abnormal glycosylation may be in part responsible for synovial hyperplasia, leading to the joint destruction in the pathogenesis of RA.
Collapse
Affiliation(s)
- H Ishino
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Kinoshita T, Nagao T, Tamura N, Akashi S, Hojo T, Hasebe T, Tsuda H. 311 Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70337-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Kikuyama M, Akashi-Tanaka S, Hojo T, Kinoshita T, Tsuda H. Utility of Intraoperative Frozen-Section Examinations of Surgical Margins: With Special Reference to the Implication of Features of Margin-Exposed Tumor Components on Further Surgical Treatment. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: The assessment of surgical margins is important in breast conserving surgery (BCS). In BCS, we usually resect additional specimens after the diagnosis of positive margin by intraoperative frozen-section examinations (IFE). However, we often experience the patients who received additional resections after positive results by IFE but no tumors were detected in the permanent sections. If we can predict the absence of residual tumor components from IFE, it may be possible to avoid additional mastectomy. In the present study, we tried to identify histological characteristics of margin-exposed tumor components on IFE as predictive factors for the residual tumor components in the additionally resected specimens. Methods: 1,835 cases underwent BCS between October 1999 and July 2008 at the National Cancer Center Hospital, Tokyo, Japan. By the review of the pathological database, we chose patients who had positive surgical margins determined by IFE and had undergone immediate additional resection. Two observers (MK, HT) reviewed the slides of frozen sections and confirmed the presence of tumor components. Results: 220 cases (12%) were eligible for this study. Within the specimens of additional resection, residual tumors existed in 114 cases (51.8%) and no tumors existed in 106 cases (48.2%). As characteristics of the primary tumors, invasive lobular carcinoma, pT3, EIC(+) and lymphatic invasion were significantly associated with the residual tumor components. As characteristics of margin-exposed tumor components on IFE, the number of positive margins, their maximum diameter and histological type were correlated with the residual tumors. The rate of detection of the residual tumors was significantly higher in the group with multiple positive margins (50/72, 69%) than in the group with a single positive margin (64/148, 43%) (p=0.0003). The residual tumors were detected in 36.5% (38/104), 60.8% (62/102), and 100% (14/14) of the groups with <6 mm, ≥6 to <20 mm, and ≥20 mm of the maximum diameter of the exposed tumor components, respectively (p=0.0005). Although there was no significant relationship in the rate between the group with exposed noninvasive components and that with exposed invasive components, the residual tumor components were detected more frequently in the group with exposed lobular carcinoma components (20/29, 69%) than in the group with exposed ductal carcinoma components (94/191, 49%) (p=0.047). By a multivariate analysis, the number of positive margins and the maximum diameter were independent risk factors of the residual tumors. Conclusion: The diagnosis of positive margins by IFE was useful for the prediction of residual tumors, and three histological properties of margin-exposed tumor components were correlated with the absence of residual tumor components. It may be possible to consider stratification of additional surgical therapy according to the characteristics of margin-exposed tumor components on IFE.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4118.
Collapse
Affiliation(s)
- M. Kikuyama
- 1National Cancer Center Hospital, Tokyo, Japan
| | | | - T. Hojo
- 1National Cancer Center Hospital, Tokyo, Japan
| | | | - H. Tsuda
- 2National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
30
|
Kinoshita T, Yamamoto N, Fujisawa T, Masuda N, Hojo T, Aogi K, Seki K, Tsuda H. A phase II trial of image-guided radiofrequency ablation of small breast carcinomas: Results of a multicenter study in Japan. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11535] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11535 Background: Locally ablative therapy of early breast cancer represents the next frontier in the evolution of minimally invasive breast conservative therapy. We performed this Phase II trial to determine the efficacy and safety of Radiofrequency (RF) ablation of small localized invasive breast carcinomas as a multicenter study in Japan. Methods: Thirty-nine patients with core-biopsy proven invasive breast cancer, T<2 cm in diameter on ultrasound and MRI were enrolled in this trial. Under ultrasound guidance, the tumor and at least a 5mm margin of surrounding breast tissue were ablated with saline- cooled RF electrode followed by surgical resection. Pathologic and immunohistochemical stains were preformed to assess tumor viability. Results: Thirty-seven patients completed the treatment. The mean tumor size on ultrasound was 1.50 cm. The mean ablation time was 12 minutes using mean power of 80.0 watts. During ablation, the tumor became progressively echogenic that correspond with the region of sever electrocautery injury at pathologic examination. Of the 37 treated patients, H&E and NADPH viability staining was available for 27 patients and in 25 (92.5%), there was no evidence of viable cancer cells. H&E and or ssDNA staining were available for another 10 patients. In total, complete thermal injury to the target lesions was recognized in 33 of 37 treated patients (89.2%). No sever adverse effect on the skin and chest wall were noted. Conclusions: RF ablation is a promising minimally invasive treatment of small breast carcinomas, as it can achieve effective cell killing with a low complication rate. We are planning a multicenter observation study for RF ablation of small breast carcinomas. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Kinoshita
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - N. Yamamoto
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - T. Fujisawa
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - N. Masuda
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - T. Hojo
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - K. Aogi
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - K. Seki
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| | - H. Tsuda
- National Cancer Center Hospital, Tokyo, Japan; Chiba Cancer Center, Chiba, Japan; Gumma Prefectral Cancer Center, Gunmma, Japan; National Osaka Medical Center, Osaka, Japan; Shikoku Cancer Center, Matuyama, Japan; JR Tokyo General Hospital, Tokyo, Japan
| |
Collapse
|
31
|
Fujishima M, Watatani M, Inui H, Hashimoto Y, Yamamoto N, Hojo T, Hirai K, Yamato M, Shiozaki H. Touch imprint cytology with cytokeratin immunostaining versus Papanicolau staining for intraoperative evaluation of sentinel lymph node metastasis in clinically node-negative breast cancer. Eur J Surg Oncol 2009; 35:398-402. [DOI: 10.1016/j.ejso.2008.03.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2007] [Accepted: 03/13/2008] [Indexed: 10/22/2022] Open
|
32
|
Kikuyama M, Akashi-Tanaka S, Yoshida M, Hojo T, Kinoshita T, Iwamoto E, Tsuda H. 0096 Usefulness of intraoperative histologic assessment of surgical margins. Breast 2009. [DOI: 10.1016/s0960-9776(09)70138-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
33
|
Hojo T, Kinoshita T, Kikuyama M, Nakano E, Akashi S, Khono T, Ando M, Katsumata N, Fujiwara Y. A clinico-pathological analysis of breast cancer patients with a family history. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6090
Background: It has been said that the high incidence of breast cancer within family lines could be investigated efficiently from genetic and environmental aspects. There could be a strong enough relationship between various carcinogenic factors and these family members. In this study, we examined the clinical and pathological characteristics of breast cancer among patients with a family history.
 Patients and Methods: We put the definition of 'Positive for a family history (FH+)' for patients who had one or more members within three generations apart from the proband. Patients with family history of breast cancer were selected out of 10506 patients who were treated in our hospital between 1962 and 2007.
 Results: There were 1272 cases in FH+ and 9234 cases in 'Negative for a family history (FH-)' group. Distribution within the family line showed the highest percentage for sisters at 37%, aunts at 25% and a mother at 25%. The family history positive breast cancer patients were around 5% in 1960-1970 although the number increased up to 18% in 2007. There was similar increasing pattern in Europe and America. The survival rate had no significant difference between FH+ and FH- statistically, but the trend was toward a better prognosis in FH+ cases. There was no relationship between family history and body mass index (BMI). The outbreak of contralateral breast cancer of FH+ was significantly higher than FH-. FH+ patients had significantly higher prevalence of a mastopathy compare to FH- patients. As for the history of other cancer species, the FH+ breast cancer patients within first generation apart from the proband had significantly higher chances compared to FH- patients.Conclusion: The breast cancer patients with family history require more detail examinations especially for the development of contralateral breast cancer. Also carcinomatous examinations are important other than breast cancer to those patients who are in the first generation apart from the proband.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6090.
Collapse
Affiliation(s)
- T Hojo
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - T Kinoshita
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - M Kikuyama
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - E Nakano
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - S Akashi
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - T Khono
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - M Ando
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - N Katsumata
- 1 National Cancer Center Hospital, Tokyo, Japan
| | - Y Fujiwara
- 1 National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
34
|
Nakano E, Hojo T, Masumura K, Kikuyama M, Akashi S, Kinoshita T. The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-5121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #5121
Purpose: It is said that triple negative breast cancer (TNBC) has poor prognosis. However, many study shows TNBC has better response to chemotherapy. Since neoadjuvant chemotherapy plays an important role to TNBC, we compared clinical and pathological response rate and prognosis between TNBC and non-TNBC.
 Patients and methods: This analysis retrospectively collected 2563 breast cancer patients for StageI-III who underwent surgery between January 2000 and September 2004 (median: 3.9 years) at National Cancer Center, Tokyo, Japan. We defined TNBC as Estorpgen and progesterone receptor negative and HER2 score 0-2+ by immnohistological report. There were 91 TNBC patients (23.1%) out of 400 patients (15.6%) who underwent neoadjuvant chemotherapy. Clinical and pathological response rate and Four-year progression free survival were compared between TNBC and non-TNBC.
 Results: There were 91 TNBC patients (23.1%). TNBC patients compared with non-TNBC had tendency to achieve cCR (91% vs 78%; p=.058) although TNBC had higher rate for cPD (6.6% vs 1.7%; p <.0001). Also TNBC tended to have higher pathological CR rate of which we classified pCR only for grade 3 cases, compared to non-TNBC (13.1% vs 7.2%; p= .042 ). Interestingly HER2 overexpression type also had higher rate for pCR. As for pPD rate, TNBC had similar rate compared to non-TNBC (5.5% v 4.3%). Four-year progression free- survival rate was higher for non-TNBC. However, TNBC had higher Four-year survival free rate only when pCR were achieved after neoadjuvant chemotherapy (99% vs 82%; p=.02).
 Conclusion: Patients with TNBC tend to have clinical and pathological response of either CR or PD. Although non-TNBC had better prognosis by four-year survival free rate, TNBC could have better prognosis if neoadjuvant chemotherapy resulted in pCR. There may be some way to predict the efficacy of neoadjuvant chemotherapy and prognosis by analyzing the shrink pattern.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5121.
Collapse
Affiliation(s)
- E Nakano
- 1 Breast Surgery Department, National Cancer Center, Tokyo, Japan
| | - T Hojo
- 1 Breast Surgery Department, National Cancer Center, Tokyo, Japan
| | - K Masumura
- 1 Breast Surgery Department, National Cancer Center, Tokyo, Japan
| | - M Kikuyama
- 1 Breast Surgery Department, National Cancer Center, Tokyo, Japan
| | - S Akashi
- 1 Breast Surgery Department, National Cancer Center, Tokyo, Japan
| | - T Kinoshita
- 1 Breast Surgery Department, National Cancer Center, Tokyo, Japan
| |
Collapse
|
35
|
Shien T, Shimizu C, Akashi-Tanaka S, Yonemori K, Kohno T, Hojo T, Ando M, Katsumata N, Kinoshita T, Fujiwara Y. Clinical Efficacy of S-1 in Pretreated Metastatic Breast Cancer Patients. Jpn J Clin Oncol 2008; 38:172-5. [DOI: 10.1093/jjco/hyn001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Shien T, Akashi-Tanaka S, Shimizu C, Hojo T, Seki K, Kohno T, Ando M, Katsumata N, Fujiwara Y, Kinoshita T. Evaluation of clinicopathological features from core needle biopsy and CT imaging as predictors of response to primary systemic therapy for operable breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11086 Background: Primary systemic therapy (PST) is standard therapy for patients with locally advanced breast cancer and increasingly used for early-stage operable disease. Clinical and pathologic responses are important prognostic parameters and clinicopathological markers to predict response to PST are needed to individualize treatment. Methods: From 1998 to 2005, 403 primary breast cancer patients were underwent curative surgical treatment after PST (Anthlacycline and/or Taxane) at NCCH. We retrospectively evaluated the clinicopathological features (age, histological type, histological grade, ER, PgR and HER-2) and classification of tumors using CT (localized tumor type and diffused tumor type) at before PST and analyzed the correlation with clinical response and pathological complete response (pCR). The log-rank statistic was used for univariate comparisons and multivariate analysis performed using Cox hazard model. Results: Overall response and pCR rate were 87% and 18%. Breast conserving surgery was performed 37% patients. Histological grade 3 (p<0.0001), ER negative (p<0.0001), PgR negative (p<0.0001), solid-tubular type (p=0.0006), age (>50) (p=0.008) and localized tumor type (p=0.02) correlated with pCR. In multivariate analysis, Histological grade 3 (p=0.01) and localized tumor type (p=0.036) were independent predictors for pCR. ER positive, histological grade 2 or 1, invasive lobular carcinoma and diffuse tumor type associated with low chemosensitivity and low breast conserving surgery rate. Conclusions: Clinical and pathological response significantly associated with ER status and histological grade. Furthermore the classification of tumor type using CT was effective to predict of response to PST. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Shien
- National Cancer Center Hospital, Tokyo, Japan
| | | | - C. Shimizu
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Hojo
- National Cancer Center Hospital, Tokyo, Japan
| | - K. Seki
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Kohno
- National Cancer Center Hospital, Tokyo, Japan
| | - M. Ando
- National Cancer Center Hospital, Tokyo, Japan
| | | | - Y. Fujiwara
- National Cancer Center Hospital, Tokyo, Japan
| | | |
Collapse
|
37
|
Kinoshita T, Shien T, Terada K, Yoshida M, Nakano E, Akashi T, Hojo T, Seki K. P69 Sentinel lymph node biopsy is feasible for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Breast 2007. [DOI: 10.1016/s0960-9776(07)70134-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
38
|
Nishimura A, Mikami Y, Hase H, Ogura T, Makinodan A, Hojo T, Sawamura K, Tokugawa S, Nagae M, Hayashida T, Mitsuhashi T, Kubo T. P15.24 Evaluation of sensory function after splint fixation in carpal tunnel syndrome using the current perception threshold test. Clin Neurophysiol 2006. [DOI: 10.1016/j.clinph.2006.06.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujioka M, Asano T, Hirata T, Kawahito Y, Satomi Y, Nishino H, Tanaka T, Hirota Y, Kubo T. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24:546-54. [PMID: 17181924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
OBJECTIVE Methotrexate (MTX) is most widely used for the treatment of rheumatoid arthritis (RA). However, it has certain drawbacks with regard to individual differences in its therapeutic effects as well as the differences in the patients' response to MTX therapy. We investigated whether multi-drug resistance-1 (ABCB1) C3435T, reduced folate carrier-1 (RFC1) G80A, 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) C347G and a 6bp-deletion polymorphism in the 3'-untranslated region of the thymidylase synthase (TYMS) gene are predictive of MTX sensitivity and its adverse effects. METHODS Patients whose last maintenance dosage of MTX was <or= 6 mg/week were regarded as responders, while patients whose last maintenance dosage of MTX was > 6 mg/week or those in whom MTX therapy was changed due to poor response to MTX were regarded as non-responders. The data of 124 RA patients who had received MTX treatment were retrospectively analyzed for polymorphisms in the ABCB1, RFC1, ATIC and TYMS genes, MTX sensitivity and MTX toxicity. RESULTS There were no significant differences in MTX sensitivity among the genotypes of RFC1, ATIC and TYMS genes. ABCB1 3435TT cases included statistically significantly more non-responders than 3435CC cases according to univariate analysis (crude odds ratio (OR) = 8.91, p = 0.001) and multivariate analysis (adjusted OR = 8.78, p = 0.038). There were no significant differences in MTX toxicity among the genotypes of all the genes. CONCLUSION These results suggested that the genetic diagnosis of ABCB1 C3435T can be applied to determine MTX sensitivity for the treatment of RA patients. However, further pharmacokinetics studies are required in this regard.
Collapse
Affiliation(s)
- R Takatori
- Dept. of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Chao Y, Chang P, Abe K, Abe K, Abe N, Adachi I, Aihara H, Akai K, Akatsu M, Akemoto M, Asano Y, Aso T, Aulchenko V, Aushev T, Aziz T, Bahinipati S, Bakich AM, Ban Y, Barbero M, Bay A, Bedny I, Bitenc U, Bizjak I, Blyth S, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Chang MC, Chen A, Chen KF, Chen WT, Cheon BG, Chistov R, Choi SK, Choi Y, Choi YK, Chuvikov A, Cole S, Danilov M, Dash M, Dong LY, Dowd R, Dragic J, Drutskoy A, Eidelman S, Eiges V, Enari Y, Epifanov D, Everton CW, Fang F, Flanagan J, Fratina S, Fujii H, Funakoshi Y, Furukawa K, Gabyshev N, Garmash A, Gershon T, Go A, Gokhroo G, Golob B, Grosse Perdekamp M, Guler H, Guo R, Haba J, Hagner C, Handa F, Hara K, Hara T, Hastings NC, Hasuko K, Hayasaka K, Hayashii H, Hazumi M, Heenan EM, Higuchi I, Higuchi T, Hinz L, Hojo T, Hokuue T, Hoshi Y, Hoshina K, Hou S, Hou WS, Hsiung YB, Huang HC, Igaki T, Igarashi Y, Iijima T, Ikeda H, Imoto A, Inami K, Ishikawa A, Ishino H, Itoh K, Itoh R, Iwamoto M, Iwasaki M, Iwasaki Y, Kagan R, Kakuno H, Kamitani T, Kang JH, Kang JS, Kapusta P, Kataoka SU, Katayama N, Kawai H, Kawai H, Kawakami Y, Kawamura N, Kawasaki T, Kent N, Khan HR, Kibayashi A, Kichimi H, Kikuchi M, Kikutani E, Kim HJ, Kim HO, Kim H, Kim JH, Kim SK, Kim TH, Kinoshita K, Kobayashi S, Koiso H, Koppenburg P, Korpar S, Krizan P, Krokovny P, Kubo T, Kulasiri R, Kumar S, Kuo CC, Kurashiro H, Kurihara E, Kusaka A, Kuzmin A, Kwon YJ, Lange JS, Leder G, Lee SE, Lee SH, Lee YJ, Lesiak T, Li J, Limosani A, Lin SW, Liventsev D, MacNaughton J, Majumder G, Mandl F, Marlow D, Masuzawa M, Matsuishi T, Matsumoto H, Matsumoto S, Matsumoto T, Matyja A, Michizono S, Mikami Y, Mimashi T, Mitaroff W, Miyabayashi K, Miyabayashi Y, Miyake H, Miyata H, Mizuk R, Mohapatra D, Moloney GR, Moorhead GF, Mori T, Mueller J, Murakami A, Nagamine T, Nagasaka Y, Nakadaira T, Nakamura I, Nakamura TT, Nakano E, Nakao M, Nakayama H, Nakazawa H, Natkaniec Z, Neichi K, Nishida S, Nitoh O, Noguchi S, Nozaki T, Ogawa A, Ogawa S, Ogawa Y, Ohmi K, Ohnishi Y, Ohshima T, Ohuchi N, Oide K, Okabe T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Park KS, Parslow N, Peak LS, Pernicka M, Perroud JP, Peters M, Piilonen LE, Poluektov A, Ronga FJ, Root N, Rozanska M, Sagawa H, Saigo M, Saitoh S, Sakai Y, Sakamoto H, Sakaue H, Sarangi TR, Satapathy M, Sato N, Schietinger T, Schneider O, Schümann J, Schwanda C, Schwartz AJ, Seki T, Semenov S, Senyo K, Settai Y, Seuster R, Sevior ME, Shibata T, Shibuya H, Shidara T, Shwartz B, Sidorov V, Siegle V, Singh JB, Somov A, Soni N, Stamen R, Stanic S, Staric M, Sugahara R, Sugi A, Sugimura T, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki S, Suzuki SY, Swain SK, Tajima O, Takasaki F, Tamai K, Tamura N, Tanabe K, Tanaka M, Tawada M, Taylor GN, Teramoto Y, Tian XC, Tokuda S, Tovey SN, Trabelsi K, Tsuboyama T, Tsukamoto T, Uchida K, Uehara S, Uglov T, Ueno K, Unno Y, Uno S, Ushiroda Y, Varner G, Varvell KE, Villa S, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe M, Watanabe Y, Widhalm L, Xie QL, Yabsley BD, Yamaguchi A, Yamamoto H, Yamamoto N, Yamamoto S, Yamanaka T, Yamashita Y, Yamauchi M, Yang H, Yeh P, Ying J, Yoshida K, Yoshida M, Yuan Y, Yusa Y, Yuta H, Zang SL, Zhang CC, Zhang J, Zhang LM, Zhang ZP, Zheng Y, Zhilich V, Ziegler T, Zontar D, Zürcher D. Evidence for direct CP violation in B0-->K+pi- decays. Phys Rev Lett 2004; 93:191802. [PMID: 15600826 DOI: 10.1103/physrevlett.93.191802] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2004] [Indexed: 05/24/2023]
Abstract
We report evidence for direct CP violation in the decay B0-->K+pi(-) with 253 fb(-1) of data collected with the Belle detector at the KEKB e(+)e(-) collider. Using 275x10(6) BB pairs we observe a B-->K+/-pi(-/+) signal with 2140+/-53 events. The measured CP violating asymmetry is A(CP)(K+pi(-))=-0.101+/-0.025(stat)+/-0.005(syst), corresponding to a significance of 3.9sigma including systematics. We also search for CP violation in the decays B+-->K+pi(0) and B+-->pi(+)pi(0). The measured CP violating asymmetries are A(CP)(K+pi(0))=0.04+/-0.05(stat)+/-0.02(syst) and A(CP)(pi(+)pi(0))=-0.02+/-0.10(stat)+/-0.01(syst), corresponding to the intervals -0.05<A(CP)(K+pi(0))<0.13 and -0.18<A(CP)(pi(+)pi(0))<0.14 at 90% confidence level.
Collapse
Affiliation(s)
- Y Chao
- Department of Physics, National Taiwan University, Taipei
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Wang MZ, Lee YJ, Abe K, Abe K, Abe T, Aihara H, Akatsu M, Asano Y, Aso T, Aushev T, Bakich AM, Ban Y, Banas E, Bay A, Behera PK, Bizjak I, Bondar A, Bozek A, Bracko M, Browder TE, Casey BCK, Chang MC, Chang P, Chao Y, Chen KF, Cheon BG, Chistov R, Choi Y, Choi YK, Drutskoy A, Eidelman S, Eiges V, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Golob B, Guo R, Hagner C, Hara T, Hazumi M, Hojo T, Hokuue T, Hoshi Y, Hou WS, Hsiung YB, Huang HC, Igaki T, Igarashi Y, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki H, Iwasaki Y, Jang HK, Kang JH, Kang JS, Katayama N, Kawai H, Kawasaki T, Kichimi H, Kim DW, Kim HJ, Kim JH, Kinoshita K, Kobayashi S, Krokovny P, Kuzmin A, Kwon YJ, Lee SH, Li J, Lin SW, Liventsev D, MacNaughton J, Majumder G, Mandl F, Matsuishi T, Matsumoto S, Matsumoto T, Mitaroff W, Miyata H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakano E, Nakao M, Nakazawa H, Nam JW, Natkaniec Z, Nishida S, Nitoh O, Ogawa S, Ohshima T, Okabe T, Okuno S, Olsen SL, Ostrowicz W, Ozaki H, Pakhlov P, Park H, Park KS, Peters M, Piilonen LE, Rozanska M, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schümann J, Schwartz AJ, Semenov S, Sevior ME, Shibuya H, Shwartz B, Sidorov V, Singh JB, Stanic S, Staric M, Sugi A, Sumiyoshi T, Suzuki SY, Takahashi T, Takasaki F, Tamai K, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Uno S, Varner G, Varvell KE, Wang CC, Wang CH, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamashita Y, Yamauchi M, Yanai H, Yeh P, Zhang ZP, Zontar D. Observation of B0-->pLambda(pi)(-). Phys Rev Lett 2003; 90:201802. [PMID: 12785883 DOI: 10.1103/physrevlett.90.201802] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2003] [Indexed: 05/24/2023]
Abstract
We report the first observation of the charmless hyperonic B decay, B0-->pLambda(pi)(-), using a 78 fb(-1) data sample recorded on the Upsilon(4S) resonance with the Belle detector at KEKB. The measured branching fraction is B(B0-->pLambda(pi)(-))=(3.97(+1.00)(-0.80)+/-0.56)x10(-6). Searches for B0-->pLambda(K)- and pSigma(0)pi(-) yield no significant signals and we set 90% confidence-level upper limits of B(B0-->pLambda(K)-)<8.2x10(-7) and B(B0-->pSigma(0)pi(-))<3.8x10(-6).
Collapse
Affiliation(s)
- M-Z Wang
- Department of Physics, National Taiwan University, Taipei
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Krokovny P, Abe K, Abe T, Adachi I, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Aushev T, Bakich AM, Ban Y, Bay A, Bedny I, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Chen KF, Cheon BG, Chistov R, Choi SK, Choi Y, Choi YK, Danilov M, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Haba J, Hara T, Hasuko K, Hayashii H, Hazumi M, Higuchi I, Higuchi T, Hojo T, Hoshi Y, Hou WS, Huang HC, Igarashi Y, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki H, Iwasaki Y, Kaneko J, Kang JH, Kang JS, Kapusta P, Katayama N, Kawai H, Kawai H, Kawakami Y, Kawasaki T, Kichimi H, Kim DW, Kim HJ, Kim HO, Kim H, Kim JH, Kobayashi S, Koppenburg P, Kuzmin A, Kwon YJ, Lange JS, Leder G, Lee SH, Lin SW, Liventsev D, MacNaughton J, Majumder G, Mandl F, Matsuishi T, Matsumoto S, Matsumoto T, Mitaroff W, Miyabayashi K, Miyake H, Miyata H, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nakazawa H, Nam JW, Natkaniec Z, Nishida S, Nitoh O, Ogawa S, Ohshima T, Okabe T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Peters M, Piilonen LE, Rozanska M, Rybicki K, Sagawa H, Sakai Y, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schümann J, Semenov S, Senyo K, Seuster R, Sevior ME, Shibuya H, Shwartz B, Sidorov V, Singh JB, Stanic S, Staric M, Sugi A, Sumisawa K, Sumiyoshi T, Suzuki S, Suzuki SY, Swain SK, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka J, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Tsuboyama T, Tsukamoto T, Uehara S, Unno Y, Uno S, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yusa Y, Zhang CC, Zhang ZP, Zhilich V, Zontar D. Observation of B0 -->D0K0 and B0 -->D0K*0 decays. Phys Rev Lett 2003; 90:141802. [PMID: 12731906 DOI: 10.1103/physrevlett.90.141802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2002] [Indexed: 05/24/2023]
Abstract
We report on a search for B(0)-->D(*0)K(*0) decays based on 85 x 10(6) BB events collected with the Belle detector at KEKB. The B(0)-->D0K(0) and B(0)-->D0K(*0) decays have been observed for the first time with the branching fractions B(B(0)-->D0K(0))=(5.0(+1.3)(-1.2)+/-0.6)x10(-5) and B(B(0)-->D0K(*0))=(4.8(+1.1)(-1.0)+/-0.5)x10(-5). No significant signal has been found for the B(0)-->D(*0)K*0) and B(0)-->D(*0)K(*0) decay modes, and upper limits at 90% C.L. are presented.
Collapse
Affiliation(s)
- P Krokovny
- Budker Institute of Nuclear Physics, Novosibirsk
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Gabyshev N, Kichimi H, Abe K, Abe K, Abe R, Abe T, Adachi I, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Aushev T, Bakich AM, Ban Y, Banas E, Bay A, Bedny I, Bizjak I, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang MC, Chang P, Chao Y, Chen KF, Cheon BG, Chistov R, Choi SK, Choi Y, Choi YK, Danilov M, Dong LY, Dragic J, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fang F, Fukunaga C, Garmash A, Gershon T, Golob B, Haba J, Hagner C, Handa F, Hara T, Hasuko K, Hayashii H, Hazumi M, Higuchi I, Hinz L, Hojo T, Hokuue T, Hoshi Y, Hou WS, Hsiung YB, Huang HC, Igaki T, Igarashi Y, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki H, Iwasaki Y, Jang HK, Kang JH, Kang JS, Kapusta P, Kataoka SU, Katayama N, Kawai H, Kawai H, Kawasaki T, Kim DW, Kim HJ, Kim HO, Kim H, Kim JH, Kim SK, Kinoshita K, Kobayashi S, Korpar S, Krizan P, Krokovny P, Kulasiri R, Kuzmin A, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Lin SW, Liventsev D, Lu RS, MacNaughton J, Majumder G, Mandl F, Matsuishi T, Matsumoto S, Matsumoto T, Mitaroff W, Miyabayashi Y, Miyake H, Miyata H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nam JW, Natkaniec Z, Nishida S, Nitoh O, Noguchi S, Nozaki T, Ogawa S, Ohshima T, Okabe T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Park KS, Peak LS, Perroud JP, Piilonen LE, Rozanska M, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Sarangi TR, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schümann J, Schwartz AJ, Semenov S, Senyo K, Seuster R, Sevior ME, Shibuya H, Shwartz B, Sidorov V, Singh JB, Soni N, Stanic S, Staric M, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki S, Suzuki SY, Swain SK, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka J, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Tsuboyama T, Tsukamoto T, Uehara S, Unno Y, Uno S, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamashita Y, Yamauchi M, Yanai H, Yuan Y, Yusa Y, Zhang CC, Zhang ZP, Zheng Y, Zhilich V, Zontar D. Observation of the decay B0-->lambda+cp. Phys Rev Lett 2003; 90:121802. [PMID: 12688867 DOI: 10.1103/physrevlett.90.121802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2002] [Indexed: 05/24/2023]
Abstract
We report the measurement of the charmed baryonic decay B(0)-->Lambda(+)(c)p with a branching fraction of (2.19(+0.56)(-0.49)+/-0.32+/-0.57)x10(-5) and a statistical significance of 5.8 sigma. The errors are statistical, systematic, and the error of the Lambda(+)(c)-->pK(-)pi(+) decay branching fraction. This is the first observation of a two-body baryonic B decay. The analysis is based on 78.2 fb(-1) of data accumulated at the Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric e(+)e(-) collider.
Collapse
Affiliation(s)
- N Gabyshev
- High Energy Accelerator Research Organization (KEK), Tsukuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Fang F, Hojo T, Abe K, Abe K, Abe T, Adachi I, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Bakich AM, Ban Y, Banas E, Bay A, Behera PK, Bizjak I, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Chen KF, Cheon BG, Chistov R, Choi SK, Choi Y, Choi YK, Danilov M, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Golob B, Hara T, Hastings NC, Hayashii H, Hazumi M, Heenan EM, Higuchi T, Hinz L, Hokuue T, Hoshi Y, Hou WS, Huang HC, Igaki T, Igarashi Y, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki H, Iwasaki Y, Jang HK, Kang JH, Kang JS, Kapusta P, Katayama N, Kawai H, Kawakami Y, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim SK, Kinoshita K, Kobayashi S, Korpar S, Krizan P, Krokovny P, Kulasiri R, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Liventsev D, Lu RS, MacNaughton J, Mandl F, Matsumoto S, Matsumoto T, Mitaroff W, Miyabayashi K, Miyake H, Miyata H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nakazawa H, Nam JW, Natkaniec Z, Nishida S, Nitoh O, Noguchi S, Nozaki T, Ogawa S, Ohshima T, Okabe T, Okuno S, Olsen SL, Onuki Y, Ozaki H, Pakhlov P, Park CW, Park H, Park KS, Perroud JP, Peters M, Piilonen LE, Ronga FJ, Root N, Rozanska M, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Sakamoto H, Satapathy M, Schneider O, Schrenk S, Schwanda C, Semenov S, Senyo K, Seuster R, Sevior ME, Shibuya H, Shwartz B, Sidorov V, Soni N, Stanic S, Staric M, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki K, Suzuki S, Takahashi T, Takasaki F, Tamura N, Tanaka J, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Trabelsi K, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Uno S, Ushiroda Y, Vahsen SE, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yashima J, Yokoyama M, Yuan Y, Yusa Y, Zhang CC, Zhang J, Zhang ZP, Zhilich V, Zontar D. Measurement of branching fractions for B-->eta(c)K(*) decays. Phys Rev Lett 2003; 90:071801. [PMID: 12633223 DOI: 10.1103/physrevlett.90.071801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2002] [Indexed: 05/24/2023]
Abstract
We report measurements of branching fractions for charged and neutral B-->eta(c)K decays where the eta(c) meson is reconstructed in the K(0)(S)K+/-pi(-/+), K+K-pi(0), K(*0)K-pi(+), and pp; decay channels. The neutral B0 channel is a CP eigenstate and can be used to measure the CP violation parameter sin(2phi(1). We also report the first observation of the B0-->eta(c)K(*0) mode. The results are based on an analysis of 29.1 fb(-1) of data collected by the Belle detector at KEKB.
Collapse
Affiliation(s)
- F Fang
- University of Hawaii, Honolulu, Hawaii, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Kaneko J, Abe K, Abe K, Abe T, Adachi I, Ahn BS, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Aushev T, Bakich AM, Ban Y, Banas E, Bartel W, Bay A, Behera PK, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Chen KF, Cheon BG, Chistov R, Choi Y, Choi YK, Danilov M, Dong LY, Eidelman S, Eiges V, Enari Y, Everton CW, Fang F, Fujii H, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Guo R, Haba J, Handa F, Hara T, Harada Y, Hastings NC, Hayashii H, Hazumi M, Heenan EM, Higuchi I, Higuchi T, Hinz L, Hojo T, Hoshi Y, Hou WS, Huang HC, Igaki T, Igarashi Y, Iijima T, Inami K, Ishikawa A, Ishino H, Itoh R, Iwasaki H, Iwasaki Y, Jang HK, Kang JH, Kang JS, Katayama N, Kawai H, Kawakami Y, Kawamura N, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim SK, Kinoshita K, Kobayashi S, Korpar S, Krizan P, Krokovny P, Kulasiri R, Kumar S, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Limosani A, Lu RS, MacNaughton J, Majumder G, Mandl F, Marlow D, Matsumoto S, Matsumoto T, Mitaroff W, Miyabayashi K, Miyabayashi Y, Miyake H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nam JW, Neichi K, Nishida S, Nitoh O, Noguchi S, Nozaki T, Ogawa S, Ohshima T, Okabe T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Park KS, Perroud JP, Peters M, Piilonen LE, Root N, Rybicki K, Sagawa H, Sakai Y, Sakamoto H, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schwanda C, Semenov S, Senyo K, Seuster R, Shibuya H, Shwartz B, Sidorov V, Singh JB, Soni N, Stanic S, Sumisawa K, Sumiyoshi T, Suzuki K, Suzuki S, Suzuki SY, Swain SK, Tajima H, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka J, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomoto M, Tomura T, Trabelsi K, Trischuk W, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Uno S, Ushiroda Y, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yashima J, Yokoyama M, Yuan Y, Yusa Y, Zhang CC, Zhang J, Zhang ZP, Zheng Y, Zhilich V, Zontar D. Measurement of the electroweak penguin process B-->X(s)l+l-. Phys Rev Lett 2003; 90:021801. [PMID: 12570535 DOI: 10.1103/physrevlett.90.021801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2002] [Indexed: 05/24/2023]
Abstract
We report the first measurement of the branching fraction for the inclusive decay B-->X(s)l(+)l(-), where l is either an electron or a muon, and X(s) is a hadronic recoil system that contains an s quark. We analyzed a data sample of 65.4 x 10(6) B meson pairs collected with the Belle detector at the KEKB e(+)e(-) asymmetric-energy collider. We find B(B-->X(s)l(+)l(-))=[6.1 +/-1.4(stat) +1.4-1.1(syst)] x 10(-6) for dilepton masses greater than 0.2 GeV/c(2).
Collapse
Affiliation(s)
- J Kaneko
- Tokyo Institute of Technology, Tokyo
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Krokovny P, Abe K, Abe K, Abe T, Adachi I, Ahn BS, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Aushev T, Bakich AM, Ban Y, Banas E, Bay A, Bedny I, Behera PK, Bizjak I, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Chen KF, Cheon BG, Chistov R, Choi SK, Choi Y, Danilov M, Dong LY, Drutskoy A, Eidelman S, Eiges V, Enari Y, Everton CW, Fang F, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Golob B, Gordon A, Guo R, Haba J, Hanagaki K, Handa F, Harada Y, Hayashii H, Hazumi M, Heenan EM, Higuchi T, Hinz L, Hojo T, Hokuue T, Hoshi Y, Hou WS, Huang HC, Igaki T, Iijima T, Inami K, Ishikawa A, Ishino H, Itoh R, Iwasaki H, Jang HK, Kaneko J, Kang JH, Kang JS, Katayama N, Kawai H, Kawakami Y, Kawamura N, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim SK, Kinoshita K, Kobayashi S, Korpar S, Krizan P, Kulasiri R, Kumar S, Kuzmin A, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Limosani A, Liventsev D, Lu RS, MacNaughton J, Majumder G, Mandl F, Marlow D, Matsuishi T, Matsumoto S, Matsumoto T, Mitaroff W, Miyabayashi K, Miyabayashi Y, Miyake H, Miyata H, Moloney GR, Mori T, Murakami A, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nakazawa H, Nam JW, Natkaniec Z, Neichi K, Nishida S, Nitoh O, Nozaki T, Ogawa S, Ohshima T, Okabe T, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Park CW, Park H, Perroud JP, Peters M, Piilonen LE, Ronga FJ, Root N, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Sakamoto H, Satapathy M, Satpathy A, Schneider O, Schwanda C, Semenov S, Senyo K, Shibuya H, Shwartz B, Sidorov V, Singh JB, Stanic S, Staric M, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki K, Suzuki S, Suzuki SY, Swain SK, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka J, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Trabelsi K, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Unno Y, Uno S, Ushiroda Y, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yashima J, Yuan Y, Yusa Y, Zhang CC, Zhang J, Zhang ZP, Zheng Y, Zhilich V, Zontar D. Observation of D+(s)K- and evidence for D+(s)pi- final states in neutral B decays. Phys Rev Lett 2002; 89:231804. [PMID: 12485001 DOI: 10.1103/physrevlett.89.231804] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2002] [Indexed: 05/24/2023]
Abstract
We report the first observation of a B meson decay that is not accessible by a direct spectator process. The channel B(0)-->D(+)(s)K- is found in a sample of 85 x 10(6) BB; events, collected with the Belle detector at KEKB, with a branching fraction B(B(0)-->D(+)(s)K-)=(4.6(+1.2)(-1.1)+/-1.3) x 10(-5). We also obtain evidence for the B0-->D(+)(s)pi(-) decay with branching fraction B(B0-->D(+)(s)pi(-))=(2.4(+1.0)(-0.8)+/-0.7) x 10(-5). This value may be used to extract a model-dependent value of |V(ub)|.
Collapse
Affiliation(s)
- P Krokovny
- Budker Institute of Nuclear Physics, Novosibirsk
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Nishida S, Nakao M, Abe K, Abe K, Abe T, Ahn BS, Aihara H, Akatsu M, Asano Y, Aushev T, Bakich AM, Ban Y, Banas E, Bartel W, Bay A, Bedny I, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Cheon BG, Chistov R, Choi SK, Choi Y, Danilov M, Dong LY, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fukunaga C, Gabyshev N, Gershon T, Gordon A, Gotow K, Guo R, Haba J, Hara T, Hayashii H, Hazumi M, Heenan EM, Higuchi I, Higuchi T, Hojo T, Hokuue T, Hoshi Y, Hou SR, Hou WS, Hsu SC, Huang HC, Igaki T, Iijima T, Inami K, Ishikawa A, Ishino H, Itoh R, Iwamoto M, Iwasaki H, Iwasaki Y, Jalocha P, Jang HK, Kang JH, Kapusta P, Kataoka SU, Katayama N, Kawai H, Kawakami Y, Kawamura N, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim TH, Kinoshita K, Krizan P, Krokovny P, Kulasiri R, Kumar S, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Lu RS, MacNaughton J, Majumder G, Mandl F, Matsumoto S, Matsumoto T, Mikami Y, Mitaroff W, Miyabayashi K, Miyake H, Miyata H, Moloney GR, Mori S, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nam JW, Natkaniec Z, Neichi K, Nitoh O, Noguchi S, Nozaki T, Ogawa S, Ohno F, Ohshima T, Okabe T, Okuno S, Olsen SL, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Park KS, Peak LS, Perroud JP, Peters M, Piilonen LE, Rozanska M, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Sakamoto H, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schwanda C, Semenov S, Senyo K, Seuster R, Sevior ME, Shibuya H, Shwartz B, Sidorov V, Singh JB, Stanic S, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki K, Suzuki S, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomoto M, Tomura T, Tovey SN, Trabelsi K, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Uno S, Ushiroda Y, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamamoto H, Yamashita Y, Yamauchi M, Yuan Y, Yusa Y, Zhang J, Zhang ZP, Zhilich V, Zontar D. Radiative B meson decays into kpigamma and kpipigamma final states. Phys Rev Lett 2002; 89:231801. [PMID: 12484998 DOI: 10.1103/physrevlett.89.231801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2002] [Revised: 09/06/2002] [Indexed: 05/24/2023]
Abstract
We report observations of radiative B meson decays into the K+pi(-)gamma and K+pi(-)pi(+)gamma final states. In the B0-->K+pi(-)gamma channel, we present evidence for decays via an intermediate tensor meson state with a branching fraction of B(B0-->K(*)(2)(1430)(0)gamma)=[1.3+/-0.5(stat)+/-0.1(syst)]x10(-5). We measure the branching fraction B(B+-->K+pi(-)pi(+)gamma)=[2.4+/-0.5(stat) +0.4-0.2(syst)]x10(-5), in which the B+-->K(*0)pi(+)gamma and B+-->K+rho(0)gamma channels dominate. The analysis is based on a data set of 29.4 fb(-1) recorded by the Belle experiment at the KEKB collider.
Collapse
|
48
|
Abe K, Abe K, Abe R, Abe T, Ahn BS, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Aushev T, Bakich AM, Ban Y, Banas E, Bay A, Bedny I, Behera PK, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Cheon BG, Chistov R, Choi SK, Choi Y, Danilov M, Dong LY, Dragic J, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fang F, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Gordon A, Guo R, Handa F, Hara T, Harada Y, Hastings NC, Hayashii H, Hazumi M, Heenan EM, Higuchi I, Higuchi T, Hojo T, Hokune T, Hoshi Y, Hoshina K, Hou SR, Hou WS, Hsu SC, Huang HC, Igaki T, Igarashi Y, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki H, Iwasaki Y, Jang HK, Kaneko J, Kang JH, Kang JS, Kapusta P, Katayama N, Kawai H, Kawakami Y, Kawamura N, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim SK, Kim TH, Kinoshita K, Korpar S, Krokovny P, Kulasiri R, Kumar S, Kuzmin A, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Liventsev D, Lu RS, MacNaughton J, Majumder G, Mandl F, Matsumoto S, Miyabayashi K, Miyake H, Miyata H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nam JW, Natkaniec Z, Neichi K, Nishida S, Nitoh O, Noguchi S, Nozaki T, Ogawa S, Ohno F, Ohshima T, Okabe T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Park KS, Peak LS, Perroud JP, Peters M, Piilonen LE, Root N, Rozanska M, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Sakamoto H, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schwanda C, Semenov S, Senyo K, Seuster R, Sevior ME, Shibuya H, Shwartz B, Sidorov V, Singh JB, Stanic S, Staric M, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki K, Suzuki S, Swain SK, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Tovey SN, Trabelsi K, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Unno Y, Uno S, Vahsen SE, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yashima J, Yuan Y, Zhang J, Zhang ZP, Zhilich V, Zontar D. Observation of B(0)-->D((*)0)pp. Phys Rev Lett 2002; 89:151802. [PMID: 12365981 DOI: 10.1103/physrevlett.89.151802] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2002] [Indexed: 05/23/2023]
Abstract
The B meson decay modes B-->Dpp; and B-->D(*)pp; have been studied using 29.4 fb(-1) of data collected with the Belle detector at KEKB. The B;(0)-->D(0)pp; and B;(0)-->D(*0)pp; decays have been observed for the first time with branching fractions B(B;(0)-->D(0)pp;)=(1.18+/-0.15+/-0.16)x10(-4) and B(B;(0)-->D(*0)pp;)=(1.20(+0.33)(-0.29)+/-0.21)x10(-4). No signal has been found for the B+-->D(+)pp; and B+-->D(*+)pp; decay modes, and the corresponding upper limits at 90% C.L. are presented.
Collapse
Affiliation(s)
- K Abe
- High Energy Accelerator Research Organization (KEK), Tsukuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abe K, Abe K, Abe R, Abe T, Adachi I, Ahn BS, Aihara H, Akatsu M, Asano Y, Aso T, Aulchenko V, Aushev T, Bakich AM, Ban Y, Banas E, Bartel W, Bay A, Behera PK, Bondar A, Bozek A, Bracko M, Brodzicka J, Browder TE, Casey BCK, Chang P, Chao Y, Cheon BG, Chistov R, Choi SK, Choi Y, Danilov M, Dong LY, Dragic J, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Gordon A, Guo R, Handa F, Hara T, Harada Y, Hastings NC, Hayashii H, Hazumi M, Heenan EM, Higuchi I, Higuchi T, Hojo T, Hokuue T, Hoshi Y, Hoshina K, Hou SR, Hou WS, Huang HC, Igaki T, Igarashi Y, Iijima T, Inami K, Ishikawa A, Itoh R, Iwamoto M, Iwasaki H, Iwasaki Y, Jang HK, Kaneko J, Kang JH, Kang JS, Kapusta P, Katayama N, Kawai H, Kawakami Y, Kawamura N, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim SK, Kim TH, Kinoshita K, Krokovny P, Kulasiri R, Kumar S, Kuzmin A, Kwon YJ, Lange JS, Leder G, Lee SH, Li J, Liventsev D, Lu RS, MacNaughton J, Majumder G, Mandl F, Matsumoto S, Matsumoto T, Miyake H, Miyata H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakano E, Nakao M, Nam JW, Natkaniec Z, Neichi K, Nishida S, Nitoh O, Noguchi S, Nozaki T, Ogawa S, Ohno F, Ohshima T, Okabe T, Okuno S, Olsen SL, Onuki Y, Ostrowicz W, Ozaki H, Pakhlov P, Palka H, Park CW, Park H, Park KS, Peak LS, Perroud JP, Peters M, Piilonen LE, Root N, Sagawa H, Saitoh S, Sakai Y, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schwanda C, Semenov S, Senyo K, Seuster R, Sevior ME, Shibuya H, Sidorov V, Singh JB, Stanic S, Staric M, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki K, Suzuki S, Swain SK, Takahashi T, Takasaki F, Tamai K, Tamura N, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Tovey SN, Trischuk W, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Unno Y, Uno S, Vahsen SE, Varner G, Varvell KE, Wang CC, Wang CH, Wang JG, Wang MZ, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yashima J, Yuan Y, Yusa Y, Zhang ZP, Zhilich V, Zontar D. Observation of double cć production in e+e- annihilation at squareroot[s] approximately 10.6 GeV. Phys Rev Lett 2002; 89:142001. [PMID: 12366036 DOI: 10.1103/physrevlett.89.142001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2002] [Indexed: 05/23/2023]
Abstract
We report the observation of prompt J/psi via double cc; production from the e+e- continuum. In this process one cc; pair fragments into a J/psi meson while the remaining pair either produces a charmonium state or fragments into open charm. Both cases have been experimentally observed. We find cross sections of sigma[e+e- -->J/psieta(c)(gamma)]xB(eta(c)-->>or=4 charged)=(0.033(+0.007)(-0.006)+/-0.009) pb and sigma(e+e- -->J/psiD(*+)X)=(0.53(+0.19)(-0.15)+/-0.14) pb and infer sigma(e+e- -->J/psicc;)/sigma(e+e- -->J/psiX)=0.59(+0.15)(-0.13)+/-0.12. These results are obtained from a 46.2 fb(-1) data sample collected near the Upsilon(4S) resonance, with the Belle detector at the KEKB collider.
Collapse
Affiliation(s)
- K Abe
- High Energy Accelerator Research Organization (KEK), Tsukuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abe K, Abe R, Abe T, Aihara H, Akatsu M, Asano Y, Aulchenko V, Aushev T, Bakich AM, Ban Y, Banas E, Bay A, Bedny I, Behera PK, Bondar A, Bozek A, Brodzicka J, Browder TE, Chang P, Chao Y, Cheon BG, Chistov R, Choi SK, Choi Y, Danilov M, Dong LY, Drutskoy A, Eidelman S, Eiges V, Enari Y, Fujii H, Fukunaga C, Gabyshev N, Garmash A, Gershon T, Golob B, Gordon A, Guo R, Handa F, Hara T, Hayashii H, Hazumi M, Heenan EM, Higuchi T, Hinz L, Hojo T, Hokuue T, Hoshi Y, Hou SR, Hou WS, Huang HC, Igaki T, Iijima T, Ishikawa A, Itoh R, Iwamoto M, Iwasaki H, Iwasaki Y, Kaneko J, Kang JH, Kang JS, Kapusta P, Katayama N, Kawai H, Kawakami Y, Kawasaki T, Kichimi H, Kim DW, Kim H, Kim HJ, Kim HO, Kim H, Kim SK, Kim TH, Kinoshita K, Korpar S, Krokovny P, Kulasiri R, Kuzmin A, Kwon YJ, Lange JS, Lee SH, Li J, Liventsev D, MacNaughton J, Majumder G, Matsumoto S, Matsumoto T, Miyabayashi K, Miyake H, Miyata H, Moloney GR, Mori T, Nagamine T, Nagasaka Y, Nakadaira T, Nakano E, Nakao M, Nam JW, Natkaniec Z, Neichi K, Nishida S, Nitoh O, Nozaki T, Ogawa S, Ohno F, Ohshima T, Okuno S, Olsen SL, Ostrowicz W, Ozaki H, Pakhlov P, Park CW, Park H, Peak LS, Perroud JP, Piilonen LE, Ronga FJ, Root N, Rybicki K, Sagawa H, Saitoh S, Sakai Y, Satapathy M, Satpathy A, Schneider O, Schrenk S, Schwanda C, Semenov S, Senyo K, Sevior ME, Shibuya H, Sidorov V, Singh JB, Stanic S, Staric M, Sugi A, Sugiyama A, Sumisawa K, Sumiyoshi T, Suzuki S, Suzuki SY, Swain SK, Takasaki F, Tamai K, Tamura N, Tanaka J, Tanaka M, Taylor GN, Teramoto Y, Tokuda S, Tomura T, Tovey SN, Trabelsi K, Tsuboyama T, Tsukamoto T, Uehara S, Ueno K, Unno Y, Uno S, Ushiroda Y, Vahsen SE, Varner G, Varvell KE, Wang CC, Wang CH, Watanabe Y, Won E, Yabsley BD, Yamada Y, Yamaguchi A, Yamashita Y, Yamauchi M, Yanai H, Yashima J, Yokoyama M, Yuan Y, Yusa Y, Zhang J, Zhang ZP, Zhilich V, Zontar D. Observation of the decay B(0)-->D(+/-)D(*-/+). Phys Rev Lett 2002; 89:122001. [PMID: 12225079 DOI: 10.1103/physrevlett.89.122001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2002] [Indexed: 05/23/2023]
Abstract
We report the first observation of the decay B(0)-->D(+/-)D(*-/+) with the Belle detector at the KEKB e(+)e(-) Collider operated at the Upsilon(4S) resonance. The sum of branching fractions B(B(0)-->D(+)D(*-))+B(B(0)-->D(-)D(*+)) is measured to be (1.17+/-0.26(+0.22)(-0.25))x10(-3) using the full reconstruction method where both charmed mesons from B0 decays are reconstructed. A consistent value [(1.48+/-0.38(+0.28)(-0.31))x10(-3)] is obtained using a partial reconstruction technique that uses only the slow pion from the D(*-)-->D(-0)pi(-) decay and a fully reconstructed D(+) to reconstruct the B(0).
Collapse
Affiliation(s)
- K Abe
- Tohoku Gakuin University, Tagajo
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|